Q2 Earnings Forecast for REGENXBIO Issued By Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Stock analysts at Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for shares of REGENXBIO in a research note issued to investors on Monday, May 12th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings per share of ($1.47) for the quarter, up from their previous estimate of ($1.49). The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO's Q3 2025 earnings at $2.02 EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($0.17) EPS, FY2026 earnings at ($1.99) EPS, FY2027 earnings at ($1.72) EPS, FY2028 earnings at ($0.34) EPS and FY2029 earnings at $0.50 EPS.

Several other equities research analysts have also weighed in on RGNX. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, March 7th. Leerink Partners set a $24.00 price target on REGENXBIO in a research report on Tuesday, March 18th. Chardan Capital restated a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a report on Thursday, March 20th. Royal Bank of Canada reiterated an "outperform" rating and issued a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. Finally, Raymond James started coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 target price on the stock. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, REGENXBIO currently has an average rating of "Moderate Buy" and a consensus price target of $31.63.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX opened at $8.33 on Thursday. The stock has a market capitalization of $417.47 million, a price-to-earnings ratio of -1.66 and a beta of 1.11. REGENXBIO has a 1-year low of $5.04 and a 1-year high of $16.85. The company has a 50 day moving average price of $7.43 and a 200 day moving average price of $7.99.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). The business had revenue of $89.01 million during the quarter, compared to analyst estimates of $105.35 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its holdings in shares of REGENXBIO by 9.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock valued at $185,000 after acquiring an additional 1,982 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in REGENXBIO by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock valued at $97,000 after purchasing an additional 2,088 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in REGENXBIO by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 27,756 shares of the biotechnology company's stock valued at $198,000 after purchasing an additional 2,326 shares during the last quarter. DnB Asset Management AS lifted its stake in shares of REGENXBIO by 20.1% in the fourth quarter. DnB Asset Management AS now owns 14,539 shares of the biotechnology company's stock worth $112,000 after buying an additional 2,434 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock worth $27,000 after buying an additional 2,510 shares during the last quarter. Institutional investors own 88.08% of the company's stock.

Insider Buying and Selling at REGENXBIO

In related news, Director Kenneth T. Mills sold 20,602 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $7.91, for a total value of $162,961.82. Following the completion of the sale, the director now owns 475,103 shares of the company's stock, valued at approximately $3,758,064.73. The trade was a 4.16% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 12.79% of the company's stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.